NCT01592331
Completed
Phase 1
A Single-Center, Randomized, Investigator/Subject-Blind, Single Dose, Placebo-Controlled, Parallel Group Study to Investigate the Pharmacodynamic and Pharmacokinetic Behavior of RO5508887 in Plasma and Cerebral Spinal Fluid Following Oral Administration in Healthy Volunteers
Overview
- Phase
- Phase 1
- Intervention
- Placebo
- Conditions
- Healthy Volunteer
- Sponsor
- Hoffmann-La Roche
- Enrollment
- 42
- Primary Endpoint
- Plasma levels of amyloid biomarkers
- Status
- Completed
- Last Updated
- 9 years ago
Overview
Brief Summary
This randomized, double-blind, placebo-controlled, parallel group study will evaluate the pharmacodynamics and pharmacokinetics of RO5508887 in healthy volunteers.
Subjects will be randomized in cohorts to receive single oral doses of either RO5508887 or placebo. In-unit period is 6 days.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Healthy male subjects, 18 to 65 years of age, inclusive. Healthy status is defined by absence of evidence of any active or chronic disease following a detailed medical and surgical history and a complete physical examination
- •Body mass index (BMI) 18 to 30 kg/m2 inclusive
- •Must agree to use a barrier method of contraception during the treatment period and for at least 30 days after the last dose of study drug
- •Donation of blood over 500 mL within 6 weeks before drug administration
Exclusion Criteria
- •Concomitant disease or condition or treatment that could interfere with the conduct of the study or would, in the opinion of the investigator, pose an unacceptable risk to the subject in this study
- •Allergy to lidocaine
- •Suspicion of regular consumption of drug of abuse
- •Regular smoker (\> 5 cigarettes, \> 1 pipeful or \> 1 cigar per day)
- •Positive for hepatitis B, hepatitis C or HIV 1 or 2 infection
- •Participation in an investigational drug or device study (last administration of study drug or installation of device) within 6 weeks before RO5508887 administration and within 5 mean half-lives of receiving previous investigational drug before RO5508887 administration. In addition, subject cannot participate unless completely recovered from previous invasive or study procedure
- •Donation of blood over 500 mL within 6 weeks before drug administration
Arms & Interventions
Placebo
Intervention: Placebo
RO5508887
Intervention: RO5508887
Outcomes
Primary Outcomes
Plasma levels of amyloid biomarkers
Time Frame: Pre-dose and up to fullow up, 8-12 days post dose
Cerebral spinal fluid levels of amyloid biomarkers
Time Frame: Pre-dose and up to 30 hours post-dose
Secondary Outcomes
- Safety: Incidence of adverse events(approximately 6 months)
- Pharmacokinetics: Plasma and cerebral spinal fluid concentrations of RO5508887 (and metabolites)(Pre-dose and up to 72 hours post-dose)
Similar Trials
Completed
Phase 1
Local Nasal Tolerability and Safety Study of 1146A in Healthy Adult ParticipantsCommon ColdNCT02832362GlaxoSmithKline30
Completed
Phase 1
To Assess Pharmacokinetics, Safety and Tolerability of TEV-48125 in Japanese and Caucasian Healthy Subjects After a Single Subcutaneous (SC) Administration of TEV-48125PharmacokineticsNCT02673567Teva Branded Pharmaceutical Products R&D, Inc.64
Completed
Phase 1
A Single-Center Study of RO5508887 in Healthy VolunteersHealthy VolunteerNCT01664143Hoffmann-La Roche36
Completed
Phase 1
A Study on Safety, Pharmacokinetics and Pharmacodynamics of RO5508887 in Healthy VolunteersHealthy VolunteerNCT01461967Hoffmann-La Roche49
Completed
Phase 1
A Study of the Safety, Tolerability and Pharmacokientics of RO5545965 in Patients With Schizophrenia on RisperidoneSchizophreniaNCT02019329Hoffmann-La Roche32